Yutao Zou

Toll-like receptor 7/8 (TLR7/8) agonists (such as resiquimod-R848) are potent immune adjuvants. However, their clinical use is limited by severe systemic toxicity. To address this challenge, prodrug strategies have emerged as a key solution. In recent …

Covalent organic frameworks (COFs) have emerged as promising candidates in cancer immunotherapy, owing to their tunable pore structures, versatile functionality, and favorable biocompatibility. This review systematically highlights recent advances in C…